...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endoscopy International Open >Cryoballoon ablation for treatment of patients with refractory esophageal neoplasia after first line endoscopic eradication therapy
【24h】

Cryoballoon ablation for treatment of patients with refractory esophageal neoplasia after first line endoscopic eradication therapy

机译：在第一线内窥镜消除治疗后，冷冻消融治疗难治性食管肿瘤患者

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and study aims?Cryoablation with the Cryoballoon device is a novel ablative therapy that uses cycles of freezing and thawing to induce cell death. This single-center prospective study evaluated the feasibility of the focal cryoablation device for the treatment of areas of refractory esophageal neoplasia in patients who had undergone first line endoscopic eradication therapy (EET). Complete remission of dysplasia (CR-D) and complete remission of intestinal metaplasia (CR-IM) at first follow-up endoscopy, durability of disease reversal, rates of stenosis and adverse events were studied. Patients and methods?Eighteen cases were treated. At baseline, nine patients had low-grade dysplasia (LGD), six had high-grade dysplasia (HGD) and three had intramucosal carcinoma (IMC). Median length of dysplastic Barrett’s esophagus (BE) treated was 3?cm. The median number of ablations per patient was 11. Each selected area of visible dysplasia received 10 seconds of ablation. One session of cryoablation was performed per patient. Biopsies were performed at around 3 months post-ablation. Results?CR-D was achieved in 78?% and CR-IM in 39?% of patients. There were no device malfunction or adverse events. Stenosis was noted in 11?% of cases. At a median follow up of 19-months, CR-D was maintained in 72?% of patients and CR-IM in 33?%. Conclusions?Cryoablation appears to be a viable rescue strategy in patients with refractory neoplasia. It is well tolerated and successful in obtaining CR-D and CR-IM in patients with treatment-refractory BE. Further trials of dosimetry, efficacy and safety in treatment-na?ve patients are underway.
机译：背景和研究旨在？与冰冻装置的冷冻剂是一种新的烧蚀治疗，它使用冻结和解冻的循环来诱导细胞死亡。该单中心前瞻性研究评估了局灶性冷冻剂装置的可行性，用于治疗患者，治疗难治性食管肿瘤肿瘤内部患者，该患者经历了一线内窥镜消除治疗（EET）。完全缓解发育不良（CR-D）并在第一次随访内窥镜检查中完全缓解肠道脑（CR-IM），疾病逆转耐久性，狭窄率和不良事件的耐久性。患者和方法？治疗了18例。在基线时，九个患者具有低级别的发育不良（LGD），六个有高档发育不良（HGD）和三个有腔内癌（IMC）。中位数的发育性Barrett的食道（BE）处理的长度为3？cm。每位患者的中位数的消融数量为11.每个选定的可见性发育不良的区域接受了10秒的消融。每位患者进行一次低温会话。活组织检查在烧蚀后3个月内进行。结果？CR-D在39岁的78℃和CR-IM中实现。没有设备故障或不良事件。 11月份的病例中注意到狭窄。在中位于19个月的中间后，CR-D在72名患者中维持，33岁以下的患者和CR-IM维持。结论？冷冻似乎是难治性肿瘤患者的可行救援策略。在治疗难治性的患者中获得CR-D和CR-IM是良好的耐受性和成功的。进一步试验治疗患者的剂量测定，疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号